title: Asian variant of intravascular lymphoma: aspects of diagnosis and the role of rituximab.
abstract: OBJECTIVE
  The Asian variant of intravascular lymphoma (AIVL) is a rare non-Hodgkin's lymphoma, characterized by hemophagocytic syndrome and the absence of neurological abnormality or skin lesions, which are typical features of classical IVL. The purpose of this study was to describe the characteristics and outcomes of AIVL patients.
  
  
  METHODS
  We conducted a retrospective chart review of AIVL patients who were admitted to our institution between January 1999 and December 2006.
  
  
  RESULTS
  Eight patients met the criteria. All patients presented with typical clinical features, including fever, hepatosplenomegaly, and cytopenia. The median time from onset to diagnosis was 4 weeks (range 2-12). Pathological diagnoses were made by bone marrow biopsy in three patients, transjugular liver biopsy in two patients, splenectomy in two patients, and percutaneous liver biopsy in one patient. All patients were treated with CHOP-like chemotherapy and rituximab was administered in five patients. Six patients achieved complete response, one achieved partial response, and two patients had central nervous system (CNS) relapse. Among the five patients treated with rituximab, four are still alive, with a median follow-up of 28 months.
  
  
  CONCLUSIONS
  A CHOP-like regimen with rituximab may be effective for AIVL cases, but, as in classical IVL, CNS prophylaxis should be considered.
authors.affiliation: Department of Hematology, Nagano Red Cross Hospital. iqo430@kc4.so-net.ne.jp
authors.forename: Ikuo
authors.initials: I
authors.lastname: Shimizu
authors.forename: Naoaki
authors.initials: N
authors.lastname: Ichikawa
authors.forename: Mihoko
authors.initials: M
authors.lastname: Yotsumoto
authors.forename: Masahiko
authors.initials: M
authors.lastname: Sumi
authors.forename: Mayumi
authors.initials: M
authors.lastname: Ueno
authors.forename: Hikaru
authors.initials: H
authors.lastname: Kobayashi
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D044466:Asian People; D016543:Central Nervous System Neoplasms / Q000188:drug therapy / Q000556:secondary; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000627:therapeutic use; D012189:Retrospective Studies; D000069283:Rituximab; D019043:Vascular Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D014750:Vincristine / Q000627:therapeutic use